|
|
Article: Palatin Technologies Initiates Phase I Safety Study of PT-141 Erectile Dysfunction Drug.
- Article from:
- Business Wire
- Article date:
- February 1, 2001
CopyrightCOPYRIGHT 2001 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Business Editors/Health & Medical Writers
PRINCETON, N.J.--(BW HealthWire)--Feb. 1, 2001
Palatin Technologies, Inc. (AMEX: PTN) today announced that it has begun enrolling patients in a Phase I safety study of the company's investigational treatment for erectile dysfunction, PT-141. The double-blind, placebo-controlled study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single, escalating doses of PT-141 administered intranasally to 52 healthy adult male subjects.
Palatin is developing PT-141 as a nasal spray for the treatment of erectile dysfunction. The company submitted an Investigational New Drug (IND) ...